Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Receives Average Rating of “Hold” from Brokerages

Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) have received a consensus recommendation of “Hold” from the five brokerages that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $29.6667.

ETON has been the topic of several research analyst reports. Zacks Research lowered Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, December 13th.

Hedge Funds Weigh In On Eton Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Oberweis Asset Management Inc. bought a new position in shares of Eton Pharmaceuticals during the 3rd quarter worth about $4,180,000. PharVision Advisers LLC acquired a new position in Eton Pharmaceuticals during the 3rd quarter worth approximately $229,000. XTX Topco Ltd acquired a new position in Eton Pharmaceuticals during the 3rd quarter worth approximately $530,000. Voleon Capital Management LP bought a new position in Eton Pharmaceuticals in the third quarter worth approximately $238,000. Finally, Quarry LP acquired a new stake in Eton Pharmaceuticals in the third quarter valued at approximately $37,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Trading Up 1.2%

ETON opened at $16.57 on Tuesday. Eton Pharmaceuticals has a twelve month low of $11.09 and a twelve month high of $23.00. The company has a fifty day moving average of $17.21 and a 200-day moving average of $16.76. The stock has a market cap of $444.41 million, a PE ratio of -66.28 and a beta of 1.17. The company has a quick ratio of 1.25, a current ratio of 1.63 and a debt-to-equity ratio of 1.19.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.20). Eton Pharmaceuticals had a negative net margin of 9.50% and a negative return on equity of 11.32%. The firm had revenue of $22.46 million for the quarter, compared to the consensus estimate of $20.47 million. On average, sell-side analysts predict that Eton Pharmaceuticals will post -0.14 EPS for the current year.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.